ISSN 1673-3770 CN 37-1437/R
Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2019, Vol. 33 ›› Issue (1): 53-58.doi: 10.6040/j.issn.1673-3770.1.2018.040
• Research Progress • Previous Articles Next Articles
Li SHA,Chuanhe LIU*(
)
CLC Number:
| 1 |
Paul WE , Zhu JF . How are T(H)2-type immune responses initiated and amplified?[J]. Nat Rev Immunol, 2010, 10 (4): 225- 235.
doi: 10.1038/nri2735 |
| 2 |
Harper RW , Zeki AA . Immunobiology of the critical asthma syndrome[J]. Clin Rev Allergy Immunol, 2015, 48 (1): 54- 65.
doi: 10.1007/s12016-013-8407-6 |
| 3 |
Dunn RM , Wechsler ME . Anti-interleukin therapy in asthma[J]. Clin Pharmacol Ther, 2015, 97 (1): 55- 65.
doi: 10.1002/cpt.11 |
| 4 |
Kearley J , Erjefalt JS , Andersson C , et al. IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways[J]. Am J Respir Crit Care Med, 2011, 183 (7): 865- 875.
doi: 10.1164/rccm.200909-1462OC |
| 5 |
Moro K , Yamada T , Tanabe M , et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells[J]. Nature, 2010, 463 (7280): 540- 544.
doi: 10.1038/nature08636 |
| 6 |
Christianson CA , Goplen NP , Zafar I , et al. Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33[J]. J Allergy Clin Immunol, 2015, 136 (1): 59- 68.e14.
doi: 10.1016/j.jaci.2014.11.037 |
| 7 |
Normansell R , Walker S , Milan SJ , et al. Omalizumab for asthma in adults and children[J]. Cochrane Database Syst Rev, 2014, (1): CD003559.
doi: 10.1002/14651858.CD003559.pub4 |
| 8 |
Storms W , Bowdish MS , Farrar JR . Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review[J]. Allergy Asthma Proc, 2012, 33 (2): 172- 177.
doi: 10.2500/aap.2012.33.3527 |
| 9 |
Long AD , Rahmaoui A , Rothman KJ , et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab[J]. J Allergy Clin Immunol, 2014, 134 (3): 560- 567.e4.
doi: 10.1016/j.jaci.2014.02.007 |
| 10 |
Gauvreau GM , Arm JP , Boulet LP , et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses[J]. J Allergy Clin Immunol, 2016, 138 (4): 1051- 1059.
doi: 10.1016/j.jaci.2016.02.027 |
| 11 |
Bel EH , Wenzel SE , Thompsen PJ , et al. Oral glucocorticoidsparing effect of mepolizumab in eosinophilic asthma[J]. N Ensl Jmed, 2014, 371 (13): 1189- 1197.
doi: 10.1056/NEJMoa1403291 |
| 12 |
Castro M , Zangrilli J , Wechsler ME , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials[J]. The Lancet Respiratory Medicine, 2015, 3 (5): 355- 366.
doi: 10.1016/S2213-2600(15)00042-9 |
| 13 |
Fitzgerald JM , Bleecker ER , Nair P , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial[J]. The Lancet, 2016, 388 (10056): 2128- 2141.
doi: 10.1016/S0140-6736(16)31322-8 |
| 14 |
Antoniu SA , Cojocaru I . Pitrakinra for asthma[J]. Expert Opin Biol Ther, 2010, 10 (11): 1609- 1615.
doi: 10.1517/14712598.2010.524203 |
| 15 |
Wenzel S , Wilbraham D , Fuller R , et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies[J]. Lancet, 2007, 370 (9596): 1422- 1431.
doi: 10.1016/S0140-6736(07)61600-6 |
| 16 |
Slager RE , Otulana BA , Hawkins GA , et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist[J]. J Allergy Clin Immunol, 2012, 130 (2): 516- 522.e4.
doi: 10.1016/j.jaci.2012.03.030 |
| 17 |
Vatrella A , Fabozzi I , Calabrese C , et al. Dupilumab: a novel treatment for asthma[J]. J Asthma Allergy, 2014, 7: 123- 130.
doi: 10.2147/JAA.S52387 |
| 18 |
Castro M , Corren J , Pavord ID , et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma[J]. N Engl J Med, 2018, 378 (26): 2486- 2496.
doi: 10.1056/NEJMoa1804092 |
| 19 |
Zayed Y , Kheiri B , Banifadel M , et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials[J]. J Asthma, 2018, 1- 10.
doi: 10.1080/02770903.2018.1520865 |
| 20 |
Corren J , Lemanske RF , Hanania NA , et al. Lebrikizumab treatment in adults with asthma[J]. N Engl J Med, 2011, 365 (12): 1088- 1098.
doi: 10.1056/NEJMoa1106469 |
| 21 |
Piper E , Brightling C , Niven R , et al. A phase Ⅱ placebo-controlled study of tralokinumab in moderate-to-severe asthma[J]. Eur Respir J, 2013, 41 (2): 330- 338.
doi: 10.1183/09031936.00223411 |
| 22 |
Brightling CE , Chanez P , Leigh R , et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Respir Med, 2015, 3 (9): 692- 701.
doi: 10.1016/S2213-2600(15)00197-6 |
| 23 |
Corren J , Parnes JR , Wang LW , et al. Tezepelumab in adults with uncontrolled asthma[J]. N Engl J Med, 2017, 377 (10): 936- 946.
doi: 10.1056/NEJMoa1704064 |
| 24 |
Kirsten A , Watz H , Pedersen F , et al. The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers[J]. Eur Respir J, 2013, 41 (1): 239- 241.
doi: 10.1183/09031936.00123612 |
| 25 |
Busse WW , Holgate S , Kerwin E , et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma[J]. Am J Respir Crit Care Med, 2013, 188 (11): 1294- 1302.
doi: 10.1164/rccm.201212-2318OC |
| 26 |
O′Byrne PM , Metev H , Puu M , et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial[J]. Lancet Respir Med, 2016, 4 (10): 797- 806.
doi: 10.1016/S2213-2600(16)30227-2 |
| 27 |
Watz H , Uddin M , Pedersen F , et al. Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma[J]. Pulm Pharmacol Ther, 2017, 45: 121- 123.
doi: 10.1016/j.pupt.2017.05.012 |
| 28 |
Berry MA , Hargadon B , Shelley M , et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma[J]. N Engl J Med, 2006, 354 (7): 697- 708.
doi: 10.1056/NEJMoa050580 |
| 29 |
Howarth PH , Babu KS , Arshad HS , et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma[J]. Thorax, 2005, 60 (12): 1012- 1018.
doi: 10.1136/thx.2005.045260 |
| 30 |
Erin EM , Leaker BR , Nicholson GC , et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma[J]. Am J Respir Crit Care Med, 2006, 174 (7): 753- 762.
doi: 10.1164/rccm.200601-072OC |
| 31 |
Taille C . Monoclonal anti-TNF-α antibodies for severe steroid-dependent asthma: a case series[J]. TORMJ, 2013, 7 (1): 21- 25.
doi: 10.2174/1874306401307010021 |
| 32 |
Rouhani FN , Meitin CA , Kaler M , et al. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation[J]. Respir Med, 2005, 99 (9): 1175- 1182.
doi: 10.1016/j.rmed.2005.02.031 |
| 33 |
Morjaria JB , Chauhan AJ , Babu KS , et al. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial[J]. Thorax, 2008, 63 (7): 584- 591.
doi: 10.1136/thx.2007.086314 |
| [1] | Chuanhe LIU. The prevalence, diagnosis and management of asthma in children in China [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 28-32. |
| [2] | Hongmeng YU,Zhuofu LIU,Qi DAI. Endoscopic sinus surgery for chronic sinusitis with asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 38-41. |
| [3] | Jie SHAO. Problems associated with allergic asthma in children [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 25-27. |
| [4] | Yu ZHANG,Xicheng SONG. Advances in interaction mechanisms and treatment strategy between chronic rhinosinusitis with nasal polyp and asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 49-52. |
| [5] | Zheng ZHU,Wanjun WANG,Qiurong HU,Jing LI. Allergen inhalation challenge in the research of allergic rhinitis and asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 42-48. |
| [6] | Qianhui QIU,Junxiao GAO. Synchronous control and long-term efficacy of specific immunotherapy for allergic rhinitis and asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 33-37. |
| [7] | HONG Haiyu, XU Guangfu, YANG Shuowei, SU Rongfei, HUANG Yili, CHI Mengshi,WANG Weihao,YANG Qintai. The prevalence and risk factors of bronchial asthma in patients with allergic rhinitis in Guangdong Province [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 94-98. |
| [8] | WANG Jianwei, ZHANG Yu, SONG Xicheng. Analysis of pulmonary function of patients who developed chronic rhinosinusitis with nasal polyps and asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 103-108. |
| [9] | JIANG Xiaodan, DONG Qingzhe, DANG Zhihong, LI Shenling, MIAO Yu, ZHAO Han, ZHANG Niankai. Dose-dependent effects of exogenous IL-17A on airway inflammatory responses in mice with allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 32(6): 73-78. |
| [10] | LIU Jie, QU Hui, LU Daowen, XIN Huaxiu, GUO Yanli. Spring pollinosis in Qingdao west district [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2018, 32(2): 70-72. |
| [11] | TU Yanyi, SHI Li, ZHAO Li, JIN Peng, ZI Xiaoxue, LI Ang, JIN Yixuan, ZHI Lili. Efficacy and safety of subcutaneous immunotherapy with house dust mite extract for allergic rhinitis. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(4): 50-55. |
| [12] | YANG Meiyan. Changes of pulmonary function and respiratory resistance in patients with allergic rhinitis and asthma after microwave treatment. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(3): 82-84. |
| [13] | ZHANG Jinling, CAI Xiaolan, LI Xuezhong, FENG Xin, QI Junjun, LIU Dayu. Study of autophagy-related genes atg3, ambra1 expressions in chronic rhinosinusitis without or with nasal polyps accompanied with asthma. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(2): 50-55. |
| [14] | WANG Guifeng, FANG Wenhao, PAN Jinbin, WEI Maobin, WANG Xiaojie, LI Yunxia. Evidences from clinical epidemiological survey for allergic rhinitis patients complicated by bronchial asthma after tonsillectomy. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(4): 42-44. |
| [15] | CHEN Guojing, CAI Xiaolan, LI Xuezhong, ZHANG Liqiang, ZHU Huitao. Perioperative treatment in endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps and asthma [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(3): 35-38. |
|